We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00131820
Recruitment Status : Completed
First Posted : August 19, 2005
Last Update Posted : March 13, 2008
Information provided by:

Study Description
Brief Summary:
This study is part of International Vaccine Institutes (IVI)'s typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries. The primary objectives of the study are to evaluate the logistic feasibility of a mass typhoid fever immunization campaign program targeting school age children in Hue City, Vietnam and to assess the knowledge, attitudes, beliefs, and practices of parents and healthcare providers in Hue City regarding typhoid fever prevention and treatment.

Condition or disease Intervention/treatment Phase
Typhoid Paratyphoid Fever Biological: Typhoid Vi vaccine Biological: Hepatitis A (control) Phase 4

Detailed Description:

Typhoid fever is a major cause of morbidity worldwide. The disease predominantly affects school-aged children, is more prevalent in urban areas, may last for several weeks and can lead to serious complications. Management of this disease is further complicated by the emergence of multi-drug resistant strains. Vaccination of high risk populations is considered the most promising strategy for the control of typhoid fever. The Vi polysaccharide vaccine has been targeted for accelerated introduction into public health programs due to the following reasons: it has been shown to have consistent efficacy results even in areas of high typhoid incidence, is given as a single dose, lacks patent protection and requires less strict cold chain requirements. A cluster-randomized trial involving the Vi polysaccharide vaccine and an active control (Hepatitis A) was designed to determine the logistic feasibility of providing Vi vaccine under actual programmatic conditions among school students in Hue City. The vaccines used in this study are internationally produced and locally licensed.

Secondary objectives of this trial are:

  • To estimate the cost-effectiveness (cost of illness, willingness to pay, vaccine delivery costs, private vaccine costs, etc) of Vi vaccination
  • To determine the effectiveness of the Vi polysaccharide vaccine following routine administration of a 1-dose schedule to school students (aged >=6 years)
  • To determine the safety and immunogenicity of the Vi vaccine
  • To study typhoid risk factors among students

A nested, prospective matched case-control study is included in the trial in order to study typhoid risk factors among children in Hue City.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100742 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam. An Evaluation of Feasibility, Public Acceptability, Effectiveness and Cost-Effectiveness in Students
Study Start Date : December 2001
Primary Completion Date : January 2007
Study Completion Date : January 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fever
U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :
  1. Logistic feasibility of mass typhoid immunization campaign
  2. Knowledge attitudes, beliefs and practices of parents and health care providers on typhoid fever prevention and treatment

Secondary Outcome Measures :
  1. Cost-effectiveness of vaccine
  2. Vaccine effectiveness
  3. Adverse events
  4. Typhoid risk factors

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   5 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Local students whose parents/guardians provide written consent to receive Vi vaccine
  • Attending any of the 66 registered schools in Hue
  • Registered in the project census
  • Lives in Hue City

Exclusion Criteria:

  • Fever (>37.5 degrees Celsius, axillary)
  • Pregnancy
  • Lactating
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00131820

National Institute of Hygiene and Epidemiology
Hanoi, Vietnam
Sponsors and Collaborators
International Vaccine Institute
National Institute of Hygiene and Epidemiology, Vietnam
Hue Preventive Medicine Center, Vietnam
Wellcome Trust
University of Western Ontario, Canada
Principal Investigator: Canh G Do, MD National Institute of Hygiene and Epidemiology, Vietnam
More Information

Responsible Party: Mr. Leon Ochiai, International Vaccine Institute
ClinicalTrials.gov Identifier: NCT00131820     History of Changes
Other Study ID Numbers: T-14
First Posted: August 19, 2005    Key Record Dates
Last Update Posted: March 13, 2008
Last Verified: March 2008

Keywords provided by International Vaccine Institute:
typhoid vaccine
enteric fever
socioeconomic costs

Additional relevant MeSH terms:
Typhoid Fever
Paratyphoid Fever
Salmonella Infections
Enterobacteriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Immunologic Factors
Physiological Effects of Drugs